MedTrace Logo

Anti-Retrovirals for Kaposi's Sarcoma

NCT00444379 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2014-08-20

No results posted yet for this study

Summary

The primary purpose of this study is to determine whether a protease inhibitor-based antiretroviral regimen is more efficacious than a non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimen in promoting the regression of KS tumor burden in persons with AIDS-related KS in Africa.

Conditions

  • Kaposi's Sarcoma
  • HIV Infections

Interventions

DRUG

Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir

Lopinavir/ritonavir 200/50mg plus Emtricitabine/Tenofovir 200/300mg versus Efavirenz 600mg plus Emtricitabine/Tenofovir 200/300mg

Sponsors & Collaborators

Principal Investigators

  • Dr. Jeffrey N Martin, MD, MPH · University of California, San Francisco

  • Dr. Edward K Mbidde, MBChB, MMed · MRC/UVRI and LSHTM Uganda Research Unit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2012-02-29
Completion
2012-07-31

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00444379 on ClinicalTrials.gov